Investor Relations

For press releases prior to June 2, 2014, the date of the spin-off of Theravance Biopharma, Inc. from Theravance, Inc., please visit Theravance, Inc. Investor Relations Press Releases.


Press Releases
Date Title and Summary View
Feb 24, 2015 GEORGE TOWN, GRAND CAYMAN -- (Marketwired) -- 02/24/15 -- Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma" or the "Company") today announced enrollment of the first patient in the Company's Phase 3 registrational study of telavancin in patients with Staphylococcus aureus bacteremia. The trial is designed to support a regulator...
Feb 10, 2015 GEORGE TOWN, GRAND CAYMAN -- (Marketwired) -- 02/10/15 -- Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma" or the "Company") today announced enrollment of the first patient in the Company's Telavancin Observational Use Registry (TOUR). The study is designed to assess how VIBATIV® (telavancin), the Company's proprietary FD...
Feb 4, 2015 GEORGE TOWN, CAYMAN ISLANDS -- (Marketwired) -- 02/04/15 -- Theravance Biopharma, Inc. (NASDAQ: TBPH) announced today that Renee Gala, Chief Financial Officer, Brett Haumann, Senior Vice President, Clinical Development and Operations, and Frank Pasqualone, Senior Vice President, Operations will participate in a fireside chat at the 2015 Leerin...
Feb 3, 2015 GEORGE TOWN, CAYMAN ISLANDS -- (Marketwired) -- 02/03/15 -- Theravance Biopharma, Inc. (NASDAQ: TBPH) (the "Company") announced today that stock options to purchase an aggregate of 34,375 of the Company's ordinary shares were granted to 14 new non-executive officer employees on February 2, 2015. The options were granted in accordance with NASD...
Feb 2, 2015 GEORGE TOWN, CAYMAN ISLANDS and PITTSBURGH, PA -- (Marketwired) -- 02/02/15 -- Theravance Biopharma, Inc. (NASDAQ: TBPH) and Mylan Inc. (NASDAQ: MYL) today announced that the two companies will partner on the development and, subject to FDA approval, commercialization of TD-4208, a novel investigational once-daily nebulized long-acting muscari...
Jan 5, 2015 SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 01/05/15 -- Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma" or the "Company") announced today, through its U.S. operating subsidiary, Theravance Biopharma US, Inc., that stock options to purchase an aggregate of 114,500 of the Company's ordinary shares were granted to seven new non-...
Dec 9, 2014 SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 12/09/14 -- Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma" or the "Company") announced today, through its U.S. operating subsidiary, Theravance Biopharma US, Inc., a reminder that the Company will host an Investor and Analyst Day for the investment community on Friday, December 12,...
Dec 3, 2014 SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 12/03/14 -- Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma" or the "Company") announced today, through its U.S. operating subsidiary, Theravance Biopharma US, Inc., that stock options to purchase an aggregate of 104,800 of the Company's ordinary shares were granted to ten new non-ex...
Nov 20, 2014 SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 11/20/14 -- Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma" or the "Company") announced today, through its U.S. operating subsidiary, Theravance Biopharma US, Inc., that the Company will host an Investor and Analyst Day for the investment community on Friday, December 12, 2014 from ...
Nov 12, 2014 SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 11/12/14 -- Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma" or the "Company") announced today, through its U.S. operating subsidiary, Theravance Biopharma US, Inc., that Rick E Winningham, Theravance Biopharma's chief executive officer, is scheduled to present at the Stifel Healthca...
1
NextLast
Add to Briefcase = add release to Briefcase
By clicking on the link below, you will leave www.theravance.com.
CancelContinue
Form content here please :)